



TSO 500 ctDNA v2 and TSO 500 HT

Powering precision oncology

Pan-tumor CGP across both tissue
and liquid biopsy to accelerate
therapeutic development

Introducing

TSO 500 ctDNA v2 and TSO 500 HT

From comprehensive genomic profiling (CGP) to confident decisions

Unlock the complexities of every tumor

NeoGenomics clinically and analytically validated, high-performance complementary CGP tests spanning both tissue and liquid biopsy deliver deep molecular insights across solid tumor indications. These tests work together seamlessly to deliver a comprehensive molecular view of tumor dynamics, enabling fast time to results and enhanced coverage and sensitivity to support insights from discovery through clinical development.

TSO 500 HT

TSO 500 HT assay streamlines solid tumor profiling by combining DNA and RNA sequencing into a single, comprehensive assay. This approach enables biomarker identification, target analysis, and resistance detection, helping to accelerate precision oncology development.

TSO 500 ctDNA v2

A comprehensive, noninvasive liquid biopsy (ctDNA) assay for solid tumors that enables biomarker discovery, resistance detection and longitudinal monitoring - empowering data-driven decisions, even when tumor tissue is limited or unavailable.



Comprehensive genomic profiling

- > 500 cancer-relevant genes
- Alterations detected: SNVs, InDels, CNVs, fusions
- Additional biomarkers: TMB, MSI



Minimal sample requirement

- TSO 500 HT: as few as 10 slides
- TSO 500 ctDNA v2: 2x 10 mL whole blood, optimal frozen plasma vol 4 mL (min 2.5 mL)



Fast turnaround time

- TSO 500 HT: Within 10 days
- TSO 500 ctDNA v2: Within 7 days



Multimodal comprehensive menu

- Complement genomic data with comprehensive IHC, ISH, FISH, Cytogenetics, Flow, and Spatial testing



Large-scale, real-world oncology data

- Inform every stage of oncology development



Dedicated scientific and bioinformatics support

- For evolving study designs and pipelines

From masked genomic alterations to breakthrough therapeutics

NeoGenomics empowers biopharma with both retrospective and prospective CGP services for comprehensive, pan-tumor molecular profiling. Our advanced, in-depth genomic analysis enables the identification of clinically actionable variants and expedites the development of targeted, precision oncology therapies.



Partner with us:

**Expedite
molecular-guided
clinical trials**

**Identify
biomarkers,
resistance
mechanisms**

**Strategically
profile patients**

**Leverage expert
scientific and
bioinformatics
support**

**Regulatory
guidance &
compliance
support**

**Access
customized
services to drive
innovation**




TSO 500 HT



TSO 500 ctDNA v2

For more information on **TSO 500 HT** or **TSO 500 ctDNA v2**, please scan or click the QR codes above, or call our Client Services team at 866.776.5907, option 3.



To learn more about NeoGenomics Pharma Services, visit us online at [NeoGenomics.com/Partners](https://www.NeoGenomics.com/Partners), call us at **866.776.5907, option 3**, or email us at ContactPharma@NeoGenomics.com.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and oncology data solutions. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service, sample-processing laboratory in Cambridge, England, United Kingdom.

CHIP = clonal hematopoiesis of indeterminate potential; CGP= Comprehensive Genomic Profiling; ctDNA = circulating tumor DNA; CNVs = copy number variants; IHC = immunohistochemistry; InDels = insertions/deletions; MSI = microsatellite instability; SNVs = single-nucleotide variants; TMB = tumor mutation burden



9490 NeoGenomics Way
Fort Myers, FL 33912

Phn: 866.776.5907
Fax: 239.690.4237

NeoGenomics.com

All trademarks are the property of their respective owners.

© 2026 NeoGenomics Laboratories. All rights reserved.

CORP-MRKT-0303 03.26